Blocking TGFβ via inhibition of the αvβ6 integrin: A possible therapy for systemic sclerosis interstitial lung disease

21Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Interstitial lung disease (ILD) is a commonly encountered complication of systemic sclerosis (SSc) and accounts for a significant proportion of SSc-associated morbidity and mortality. Its pathogenesis remains poorly understood, and therapies that treat SSc ILD are suboptimal, at best. SSc ILD pathogenesis may share some common mechanisms with other fibrotic lung diseases, in which dysregulation of lung epithelium can contribute to pathologic fibrosis via recruitment or in situ generation and activation of fibroblasts. TGF, a master regulator of fibrosis, is tightly regulated in the lung by the integrin v6, which is expressed at low levels on healthy alveolar epithelial cells but is highly induced in the setting of lung injury or fibrosis. Here we discuss the biology of v6 and present this integrin as a potentially attractive target for inhibition in the setting of SSc ILD. Copyright © 2011 Tamiko R. Katsumoto et al.

Cite

CITATION STYLE

APA

Katsumoto, T. R., Violette, S. M., & Sheppard, D. (2011). Blocking TGFβ via inhibition of the αvβ6 integrin: A possible therapy for systemic sclerosis interstitial lung disease. International Journal of Rheumatology. https://doi.org/10.1155/2011/208219

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free